Evusheld recommended for market authorisation in EU
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Vault PromoMats helps life sciences companies speed the creation, review, and distribution of compliant content. Built-in digital asset management enables content reuse and reduces spend on promotional materials
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
The expansion makes Exothera one of the largest viral vector facilities in Europe
Sputnik Light is the first component of Sputnik V
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Successful proposals will secure fully funded postdoctoral research positions
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Subscribe To Our Newsletter & Stay Updated